Search results
Results from the WOW.Com Content Network
Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast . [ 1 ]
This is an accepted version of this page This is the latest accepted revision, reviewed on 16 February 2025. Cancer that originates in mammary glands Medical condition Breast cancer An illustration of breast cancer Specialty Surgical oncology Symptoms A lump in a breast, a change in breast shape, dimpling of the skin, fluid from the nipple, a newly inverted nipple, a red scaly patch of skin on ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Histopathologic types of breast cancer, with relative incidences and prognoses, with "invasive lobular carcinoma" at top right. Invasive lobular carcinoma (ILC) is breast cancer arising from the lobules of the mammary glands. [1]
Invasive carcinoma NST is a diagnosis of exclusion, which means that for the diagnosis to be made all the other specific types must be ruled out. There are several rare sub-types of invasive carcinoma NST including pleomorphic carcinoma , carcinoma with osteoclast-like stromal giant cells , carcinoma with choriocarcinomatous features , and ...
Adenocarcinoma in situ (AIS) of the lung —previously included in the category of "bronchioloalveolar carcinoma" (BAC)—is a subtype of lung adenocarcinoma.It tends to arise in the distal bronchioles or alveoli and is defined by a non-invasive growth pattern.
Chromogenic in situ hybridization (CISH) is a cytogenetic technique that combines the chromogenic signal detection method of immunohistochemistry (IHC) techniques with in situ hybridization. [ 1 ] [ 2 ] It was developed around the year 2000 as an alternative to fluorescence in situ hybridization (FISH) for detection of HER-2/neu oncogene ...
Most people who take a drug test take a presumptive test, cheaper and faster than other methods of testing. However, it is less accurate and can render false results. The FDA recommends for confirmatory testing to be conducted and the placing of a warning label on the presumptive drug test: "This assay provides only a preliminary result.